Bachem Revenue: How the Swiss Peptide Maker Earns Its Money

Bachem's revenue comes from manufacturing peptides and oligonucleotides for other companies, not from selling its own branded medicines. The Swiss group reports sales in Swiss francs twice a year, and its top line has grown substantially over the past decade on the back of peptide-based drugs. Because a small number of large manufacturing contracts drive a big share of the total, each results release carries more weight than a typical industrial earnings report.

How Bachem Earns Its Money: Two Core Business Lines

Understanding the bachem company starts with its two-part structure. Bachem operates as a contract development and manufacturing organization (CDMO) for pharmaceutical partners while also running a catalog business that sells research-grade material to laboratories.

• Commercial manufacturing: GMP peptides and oligonucleotides produced at large scale for partners whose drugs are in late-stage trials or already approved. These contracts are few, long, and valuable.
• Research and specialty chemicals: catalog peptides, bachem amino acids, building blocks, and resins sold in small quantities. This revenue is steady and high-margin, but each order is individually small.

The bachem oligonucleotide franchise is the newer leg of the business, serving siRNA and antisense developers who need GMP material. Meanwhile, catalog items generate repeat orders rather than blockbuster contracts.

Revenue stream	What Bachem sells	Typical customer	Main growth driver
Commercial peptides	GMP peptide APIs at kilo-to-ton scale	Pharma and biotech with marketed drugs	Peptide therapeutics, including GLP-1 drugs
Research and specialty chemicals	Catalog peptides, amino acid derivatives, resins	Academic labs and early-stage biotech	Recurring R&D budgets
Oligonucleotides	GMP oligonucleotide APIs and intermediates	siRNA and antisense developers	New nucleic acid modalities

What Bachem's Reported Sales Actually Look Like

Bachem reports in Swiss francs but highlights growth in local currencies, because a strong franc can make underlying demand look weaker than it is. Reported group sales were roughly CHF 529 million in 2022 and roughly CHF 590 million in 2023.

Half-year figures are published in the summer and can swing sharply based on delivery timing. A single large shipment moving from June to July can flip a growth rate from positive to negative, which is why investors watch the full-year report and medium-term guidance more than any single half.

Every bachem press release covering results includes sales by business unit, an EBITDA figure, and capital spending plans. Reading the primary release beats reading a summary, because currency restatements and one-off items change the headline numbers.

The Demand Drivers Behind Bachem Revenue Growth

Three forces explain most of Bachem's revenue trajectory.

1. Peptide therapeutics. GLP-1 drugs for diabetes and obesity require peptide API at volumes the industry had never produced before. Bachem is one of a small number of independent manufacturers able to supply that volume.
2. New modalities. Oligonucleotide drugs, including siRNA, need the same GMP capacity, documentation, and regulatory track record.
3. Outsourcing. Pharmaceutical companies increasingly buy peptides from specialists instead of building their own capacity.

These drivers are structural rather than cyclical, but they are not guaranteed. If a partner's program fails, or a competitor wins the next contract, revenue can step down as quickly as it stepped up.

Margins, Capital Spending, and Capacity Expansion

Revenue alone does not tell you whether Bachem is performing well. The company invests heavily in production capacity, which holds back near-term free cash flow while supporting future sales. A bachem capital increase helped fund earlier expansion rounds in Switzerland and the United States, and spending on new lines has continued since.

EBITDA margins have historically sat in the high-20s to around 30 percent, which is strong for contract manufacturing. That margin reflects quality systems, regulatory approvals, and the switching costs customers face once a drug is filed with a regulator.

Higher sales do not automatically produce higher profit. When a new plant opens, underused capacity can drag on margins for several quarters before volumes catch up.

Where Bachem's Revenue Comes From Geographically

North America and Europe generate most of Bachem's sales, with Asia contributing a smaller but growing share. Contracts are typically priced in US dollars or euros, so currency moves can flatter or dent reported franc revenue even when operations have not changed.

Bachem rarely names individual customers, but its annual report discusses customer concentration. That section deserves attention, because dependence on a handful of programs is the single biggest risk to the revenue line.

How to Check Bachem Revenue Figures Yourself

Figures get revised, third-party summaries lag, and different outlets quote different currencies, so primary sources are the only reliable option. Quality documentation such as a bachem coa matters to customers receiving shipments, but investors should focus on reports filed with the company and published on its investor relations page.

Source	What you get	How often it appears
Half-year report	First-half sales, EBITDA, updated outlook	Once a year, in summer
Full-year report and media release	Audited annual sales, segment split, dividend proposal	Once a year, in late winter
Investor relations website	Presentations, webcasts, archived reports	Continuously updated

Bachem revenue is best understood as a leveraged bet on peptide and oligonucleotide medicines reaching the market. Strong demand for those therapies supports the sales line, while plant openings, currency swings, and contract timing determine how much of that revenue reaches the bottom line. Nothing here is investment advice, and readers making financial or health decisions should consult a licensed professional.

COMMON QUESTIONS

Frequently Asked Questions

How much revenue does Bachem generate?

Bachem reported group sales of roughly CHF 590 million for its 2023 financial year, up from roughly CHF 529 million in 2022. The company reports in Swiss francs and emphasizes local-currency growth, so the exact headline figure shifts with exchange rates. The latest half-year or full-year press release is the most reliable source.

What is Bachem's biggest source of revenue?

Commercial peptide manufacturing for pharmaceutical partners is Bachem's largest revenue stream. These are GMP contracts for drugs in late-stage development or already on the market, and they generate far more revenue per customer than catalog sales. Oligonucleotide manufacturing is the smaller but faster-growing second leg.

Is Bachem a profitable company?

Bachem has historically posted EBITDA margins in the high-20s to around 30 percent, which is high for a contract manufacturer. Profitability depends heavily on capacity utilization, since new plants carry costs before they generate matching sales. Investors should check the most recent annual report for current margin figures.